A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Proof-of-Concept Study to Investigate Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared With Tirzepatide Alone in Participants With Obesity Aged 55 Years and Over (STRIDES)
Latest Information Update: 17 Mar 2025
At a glance
- Drugs Azelaprag (Primary) ; Tirzepatide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms STRIDES
- Sponsors BioAge Labs
Most Recent Events
- 13 Mar 2025 Status changed from suspended to discontinued.
- 07 Jan 2025 Planned End Date changed from 1 Dec 2025 to 28 Feb 2025.
- 07 Jan 2025 Planned primary completion date changed from 1 Sep 2025 to 31 Jan 2025.